NCT01229644View on ClinicalTrials.gov

Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

December 31, 2012

Conditions
Glioma
Interventions
DRUG

Crenolanib (CP-868,596)

Highly potent inhibitor of both PDGFR receptors alpha and beta

Trial Locations (1)

75390

Harold Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas

Sponsors
All Listed Sponsors
lead

Arog Pharmaceuticals, Inc.

INDUSTRY